<div id="readability-page-1">Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome. The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and cong...</div>

Soleno治疗

<p>Soleno Therapeutics（SLNO）的股价在 Scorpion Capital 披露其空头头寸后下跌了 7%，报告强调了与其用于普拉德 - 威利综合症的药物 Vykat XR 相关的风险。该报告引发了对潜在的前糖尿病/糖尿病、肺水肿及其他健康问题的担忧。尽管如此，散户投资者对该股票的未来仍持乐观态度</p>

Soleno 治疗的股票下跌，因为 Scorpion Capital 披露了空头头寸，但散户投资者尚未表现出悲观情绪